Genetic Signatures (GSS) H2 2025 earnings summary

Executive summary

• Strategic refocus implemented, shifting product and personnel priorities to align with future growth opportunities and new leadership appointments, including a new CEO and non-executive directors.

• Year marked by transition, operational streamlining, and renewed focus on core diagnostic strengths.

• Emphasis on early infectious disease detection and combating antimicrobial resistance with proprietary PCR technology.

• Revenue increased 63% year-over-year to $15.9 million, driven by strong respiratory testing and extended season in Australia.

• First US commercial contracts signed, marking a milestone in global expansion.

Financial highlights

• Total revenue for FY25 reached $15.9 million, up from $9.8 million in FY24.

• Gross margin improved to 55% (up from 53% in FY24) due to higher revenue.

• Statutory loss was $20.1 million, including a $7 million impairment expense; underlying losses reduced by 28% to $12.7 million.

• Cash reserves at $30.9 million with no debt as of 30 June 2025; net operating cash outflows of $12.3 million (including $5 million R&D rebate/grant).

• $5.4 million in other income from R&D tax incentives and interest income.

Outlook and guidance

• Expectation of continued revenue growth in Australia and EMEA, with at least four major EMEA accounts targeted.

• Focus on retaining and expanding the Australian customer base and preparing for major procurement opportunities.

• US focus: roll out revised go-to-market strategy to drive revenue in FY26.

• Ongoing investment in product optimization and next-generation automated hardware and software solutions.

• No specific guidance on timing for operating cash flow break-even, but disciplined cost management and sales growth remain priorities.